57 Results for "

BB1

" in MedChemExpress (MCE) Product Catalog:
Products (57)

57 Results for "BB1" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-103286
CAS No.: 204067-01-6
Purity:  99.38%
Target:  

Bombesin Receptor

Research Areas:  

Cancer

PD176252 is a potent antagonist of neuromedin-B preferring (BB1) and gastrin-releasing peptide-preferring (BB2) receptor with Kis of 0.17 nM and 1 nM for human BB1 and BB2 receptors, and 0.66 nM, 16 nM for Rat BB1 and BB2 receptors, respectively; PD176252 is also an agonist of N-Formyl peptide receptor1/2 (FPR1/FPR2), with EC50s of 0.31 and 0.66 μM in HL-60 cells.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-103277A
Purity:  96.20%
Target:  

Bombesin Receptor

BIM 23042 TFA, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca 2+ release [1] .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P84266
Synonyms: B7; BB1; B7-1; B7.1; LAB7; CD28LG; CD28LG1

Host:  

Mouse

Application:  

IHC-P, FC, ELISA

Reactivity:  

Human, Mouse, Rat, Rabbit

loading...
    loading...
Cat. No.: HY-P99419
CAS No.: 2253937-12-9
Synonyms: GEN1046

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer [1] .
loading...
    loading...
Cat. No.: HY-P991149
CAS No.: 2966936-23-0
Synonyms: YH32367; ABL105

Target:  

TNF Receptor

Research Areas:  

Cancer

Nesfrotamig (YH32367; ABL105) is a bispecific activator targeting HER2 and 4-1BB. The Kd values of Nesfrotamig for human HER2 and human 4-1BB are 0.48 nM and 3.36 nM, respectively. By blocking tumor cell growth signals, activating HER2-dependent local 4-1BB in tumors to maintain T cell survival, and inducing NK cell-mediated antibody-dependent cellular cytotoxicity, Nesfrotamig enhances the cytotoxicity and tumor infiltration ability of immune cells. Nesfrotamig promotes the generation of tumor-specific memory T cells, drives T cell-mediated tumor lysis, exhibits significant anti-tumor efficacy against both HER2-positive and HER2-low-expressing tumors, and shows synergistic activity when combined with anti-PD-1 antibodies. In cynomolgus monkey studies, Nesfrotamig demonstrates good safety and is suitable for research related to HER2-positive and HER2-low-expressing tumors [1] .
loading...
    loading...
Cat. No.: HY-P99572
CAS No.: 2253891-70-0
Synonyms: BNT-312; DuoBody-CD40x-4-1BB; GEN1042

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology Cancer

Tecaginlimab (BNT-312) is a Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB. Tecaginlimab can enhance priming and reactivation of tumor-specific immunity [1].
loading...
    loading...
Cat. No.: HY-P99605
CAS No.: 2218515-90-1
Synonyms: PRS 343

Target:  

EGFR TNF Receptor

Research Areas:  

Cancer

Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (Kd=0.3 nM) and human monomeric CD137 (4-1BB; Kd=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research [1] .
loading...
    loading...
Cat. No.: HY-116216
CAS No.: 204066-82-0
Purity:  98.78%
Target:  

Bombesin Receptor

Research Areas:  

Cancer

PD 168368 is a potent, competitive, and selective neuromedin B receptor (NMB-R) antagonist with the Ki of 15–45 nM [1]. PD 168368 is neuromedin B receptor (NMBR; IC50=96 nM) / gastrin-releasing peptide receptor (GRPR IC50=3500 nM) antagonist . PD 168368 also is a mixed FPR1/FPR2/FPR3 agonist with EC50s of 0.57, 0.24, and 2.7 nM, respectively .
loading...
    loading...
Cat. No.: HY-P990017
CAS No.: 2417199-08-5
Synonyms: CD19-4-1BBL; RO7227166; RG6076

Target:  

CD19

Research Areas:  

Cancer

Englumafusp alfa (CD19-4-1BBL; RO7227166) is a fusion construct comprised of a CD19-specific antibody domain fused to a trimerized extracellular domains of human 41BBL. Englumafusp alfa promotes CD19-specific 4-1BB cross-linking on the surface of T and NK cells [1].
loading...
    loading...
Cat. No.: HY-P99914
CAS No.: 2559704-23-1
Synonyms: GNC-038
Emfizatamab (GNC-038) is a monoclonal antibody against CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3 and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or PD-L1 on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia [1] .
loading...
    loading...
Cat. No.: HY-P990738
CAS No.: 2539845-73-1
Synonyms: ES-101; INBRX-105

Target:  

TNF Receptor PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Enristomig (ES-101) is a multispecific antibody. Enristomig is both a PD-L1 antagonist and a conditional agonist of 4-1BB. Enristomig can be used for research on PD-L1 expressing tumors [1].
loading...
    loading...
Cat. No.: HY-P990742
CAS No.: 2762499-30-7
Synonyms: TJ-CD4B; ABL111; TJ033721

Target:  

TNF Receptor Claudin

Research Areas:  

Inflammation/Immunology Cancer

Givastomig (ABL111, TJ033721) is a bispecific antibody (BsAb) inhibitor. Givastomig can specifically binds to Claudin18.2 (CLDN 18.2) on the surface of cancer cells and 4-1BB (CD137, TNFRSF9) on the surface of activated T cells and natural killer (NK) cells. Givastomig is engineered to contain a single Fc-domain mutation (asparagine to alanine) to eliminate Fc-effector function. Givastomig-bound cell lines expressing a range of CLDN18.2 levels with high affinity and induced 4-1BB activation only in the context of CLDN18.2 binding. Givastomig can be used for the study of colon carcinoma [1].
loading...
    loading...
Cat. No.: HY-160959
CAS No.: 946074-35-7
Target:  

nAChR

Research Areas:  

Neurological Disease

AN317 is a selective agonist for α6β2-containing nicotinic acetylcholine receptor (nAChR) with Ki of 6.2 nM and 4.1 nM, for α6/α3β2β3 receptor and α4β2 receptor, respectively. AN317 induces dopamine release in the synaptosomes of the rat striatum, enhances dopaminergic neuronal activity in substantia nigra, and exhibits protective efficacy to rat neurons against dopamine neurotoxin MPP +. AN317 exhibits good pharmacokinetic characteristics in rats. AN317 penetrates the blood-brain barrier (BB) .
loading...
    loading...
Cat. No.: HY-103277
CAS No.: 111857-96-6
Target:  

Bombesin Receptor

BIM 23042, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca 2+ release [1] .
loading...
    loading...
Cat. No.: HY-P990067
CAS No.: 2639688-77-8
Synonyms: ATOR-1017

Target:  

TNF Receptor

Research Areas:  

Cancer

Evunzekibart (ATOR-1017) is an Fc-γ receptor conditional 4-1BB agonist and IgG4-type antibody. Evunzekibart can be used as monotherapy or in combination with anti-PD1 to exert anticancer activity.
loading...
    loading...
Cat. No.: HY-13338
CAS No.: 56341-08-3
Purity:  99.96%
Target:  

Adrenergic Receptor

Research Areas:  

Cardiovascular Disease

Mabuterol is a selective and orally active beta-2 adrenergic receptor (ADRB2) agonist. Mabuterol inhibits the proliferation and suppresses the increase of intracellular Ca2+ induced by PDGF-BB. Mabuterol suppresses the protein expressions of Drp-1, cyclinD1 and PCNA and enhanced the expression of Mfn-2 induced by PDGF-BB .
loading...
    loading...
Cat. No.: HY-P990778
CAS No.: 2756879-35-1
Synonyms: ATG-101

Target:  

TNF Receptor PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Xirestomig (ATG-101) is a tetravalent "2+2″ PD-L1×4-1BB bispecific antibody. Xirestomig binds PD-L1 and 4-1BB concurrently, with a greater affinity for PD-L1, and potently activated 4-1BB+ T cells when cross-linked with PD-L1-positive cells. Xirestomig activates exhausted T cells upon PD-L1 binding. Xirestomig displays potent antitumor activity in numerous in vivo tumor models, including those resistant or refractory to immune checkpoint inhibitors (ICIs) [1].
loading...
    loading...
Cat. No.: HY-157084
Target:  

ROS Kinase Bacterial

Research Areas:  

Infection

HS-291 is a HtpG inhibitor of Borrelia burgdorferi (Bb). HS-291 contains BX-2819 (high affinity for Bb HtpG), PEG linker, and Verteporfin (HY-B0146) (a photoactive toxin).HS-291 produces reactive oxygen species under light activation to oxidize HtpG and a discrete protein subset near chaperone proteins and can quickly and irreversibly inactivate Bb .
loading...
    loading...
Cat. No.: HY-P991070

Target:  

TNF Receptor

Research Areas:  

Cancer

ADG-106 is a fully human agonistic monoclonal IgG4 antibody against CD137 (4-1BB). ADG-106 has the mechanism to activate CD137 via strong FcγRIIB-mediated crosslinking while antagonizing CD137 ligands. The isotype control for ADG-106 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) [1].
loading...
    loading...
Cat. No.: HY-RS17387
Research Areas:  

Others

Ceacam1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ceacam1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...